A health worker shows a dose of China’s Sinopharm Covid-19 vaccine at a vaccination center in the Jordanian capital Amman on January 13, 2021.
Khalil Mazraawi | AFP | Getty Images
BEIJING — Sinopharm, a state-owned giant in China’s coronavirus vaccine development, announced its chairman left the board Tuesday.
The company cited personal reasons for Li Zhiming’s resignation, according to a filing for the Hong Kong-listed company. Li Hui, a director and audit committee member of Sinopharm subsidiary China National Medicines Corp. also resigned Tuesday due to personal reasons, a separate filing disclosed.
In late December, Chinese authorities approved a vaccine developed by a Beijing-based…